# EDGAR Filing Document

**Accession Number:** 0001863127
**File Stem:** 0001193125-26-051409
**Filing Date:** 2026-2
**Character Count:** 14908
**Document Hash:** c8b64a136d52f23ddf537c1ebf5fd906
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-051409.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001193125-26-051409

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tyra Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001863127
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831476348
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92865
- **FILM NUMBER:** 26632997

**BUSINESS ADDRESS:**
- **STREET 1:** 2656 STATE STREET
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92008
- **BUSINESS PHONE:** (619) 728-4760

**MAIL ADDRESS:**
- **STREET 1:** 2656 STATE STREET
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92008
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Canaan XI L.P.
- **CENTRAL INDEX KEY:** 0001712417

**ORGANIZATION NAME:**
- **EIN:** 981377917
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 855 OAK GROVE, SUITE 201
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025
- **BUSINESS PHONE:** 650-854-8092

**MAIL ADDRESS:**
- **STREET 1:** 855 OAK GROVE, SUITE 201
- **CITY:** MENLO PARK
- **STATE:** CA
- **ZIP:** 94025

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Issuer:** Tyra Biosciences, Inc.

**Title of Class of Securities:** COMMON STOCK, $0.0001 PAR VALUE PER SHARE

**CUSIP Number:** 90240B106

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Canaan XI L.P. | Names of Reporting Persons<br>Canaan XI L.P. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2930444 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2930444 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2930444 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2930444 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.5% | Percent of Class Represented by Amount in Row (9)<br>5.5% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

---

| 1. | Names of Reporting Persons<br>Canaan Partners XI LLC | Names of Reporting Persons<br>Canaan Partners XI LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>2930444.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>2930444.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2930444.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>2930444.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>5.5% | Percent of Class Represented by Amount in Row (9)<br>5.5% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

---

| 1. | Names of Reporting Persons<br>Canaan 2020+ Co-Investment L.P. - Series 7 | Names of Reporting Persons<br>Canaan 2020+ Co-Investment L.P. - Series 7 |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>443885.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>443885.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>443885.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>443885.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.8% | Percent of Class Represented by Amount in Row (9)<br>0.8% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

---

| 1. | Names of Reporting Persons<br>Canaan Partners 2020+ Co-Investment LLC | Names of Reporting Persons<br>Canaan Partners 2020+ Co-Investment LLC |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [x] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>DE | Citizenship or Place of Organization<br>DE |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>443885.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>443885.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>443885.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>443885.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>0.8% | Percent of Class Represented by Amount in Row (9)<br>0.8% |
| 12. | Type of Reporting Person (See Instructions)<br>OO | Type of Reporting Person (See Instructions)<br>OO |

**Comment for Type of Reporting Person:** Based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.

---

**Item 1(a). Name of Issuer:**
Tyra Biosciences, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
2656 State Street, Carlsbad, CA 92008

**Item 2(a). Name of Person Filing:**
(i)     Canaan XI L.P., a Cayman Islands limited partnership ( "Canaan XI");
(ii)    Canaan Partners XI LLC, a Delaware limited liability company ("Canaan XI GP");
(iii)   Canaan 2020+ Co-Investment L.P. - Series 7, a Delaware limited partnership ("Canaan Series 7");and
(iv)   Canaan Partners 2020+ Co-Investment, LLC, a Delaware limited liability company ("Canaan 2020+GP").

**Item 2(b). Address of Principal Business Office:**
The address of the principal business office of each of the Reporting Persons is 855 Oak Grove, Suite 201, Menlo Park, California 94025.

**Item 2(c). Citizenship:**
See Item 2(a) above.

**Item 2(d). Title of Class of Securities:**
COMMON STOCK, $0.0001 PAR VALUE PER SHARE

**Item 2(e). CUSIP Number:**
90240B106

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

(i) Canaan XI directly owns 2,930,444 shares of Common Stock, which represents approximately 5.5% of the outstanding shares of Common Stock.
(ii) Canaan XI GP is the general partner of Canaan XI and may be deemed to beneficially own  2,930,444 shares of Common Stock, which represents approximately 5.5% of the outstanding shares of Common Stock.
(iii) Canaan Series 7 directly owns 443,885 shares of Common Stock, which represents approximately 0.8% of the outstanding shares of Common Stock.
(iv) Canaan 2020+ GP is the general partner of Canaan Series 7 and may be deemed to beneficially own 443,885 shares of Common Stock, which represents approximately 0.8% of the outstanding shares of Common Stock.

**(b) Percent of class:**

The percent of class of the outstanding shares of Common Stock beneficially owned by the Reporting Persons in Item 4(a) are based on 53,372,098 shares of Common Stock outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025.
%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

(1) Canaan XI: 2,930,444 shares of Common Stock;
(2) Canaan XI GP: 2,930,444 shares of Common Stock;
(3) Canaan Series 7: 443,885 shares of Common Stock; and
(4) Canaan 2020+ GP: 443,885 shares of Common Stock.

**(ii) Shared power to vote or to direct the vote:**

None.

**(iii) Sole power to dispose or to direct the disposition of:**

(1) Canaan XI: 2,930,444 shares of Common Stock;
(2) Canaan XI GP: 2,930,444 shares of Common Stock;
(3) Canaan Series 7: 443,885 shares of Common Stock; and
(4) Canaan 2020+ GP: 443,885 shares of Common Stock.

**(iv) Shared power to dispose or to direct the disposition of:**

None.

**Item 5. Ownership of Five Percent or Less of a Class.**

[ ] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

—

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Canaan XI L.P.**

**Date:** 02/13/2026

**By:** /s/ Nancy Levenson

**Name & Title:** Nancy Levenson, Attorney-in-Fact

**Canaan Partners XI LLC**

**Date:** 02/13/2026

**By:** /s/ Nancy Levenson

**Name & Title:** Nancy Levenson, Attorney-in-Fact

**Canaan 2020+ Co-Investment L.P. - Series 7**

**Date:** 02/13/2026

**By:** /s/ Nancy Levenson

**Name & Title:** Nancy Levenson, Attorney-in-Fact

**Canaan Partners 2020+ Co-Investment LLC**

**Date:** 02/13/2026

**By:** /s/ Nancy Levenson

**Name & Title:** Nancy Levenson, Attorney-in-Fact